ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025
Redox modulation of the complement cascade contributes to synapse loss in Alzheimer's disease.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Baseline cerebrospinal fluid complement balance is associated with longitudinal memory decline in relation to plasma p‑tau181 levels in mild cognitive impairment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- The Glial Autophagy-Lysosomal-Inflammation Axis in Alzheimer's Disease: a Unifying Mechanistic Framework.Molecular neurobiology · 2026Review
- Aberrant Protein S-Nitrosylation Mimics the Effect of Rare Genetic Mutations in Neurodegenerative Diseases.Journal of neurochemistry · 2026Review
- Gasotransmitter signaling in the brain: New frontiers for therapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Neuroinflammation is characterized by activation of the immune response in the central nervous system (CNS). In Alzheimer's disease (AD), this involves stimulation of glial cells, including microglia and astrocytes, that surround senile plaques and affected neurons. The complement system is a crucial component of the innate immune system, responsible for rapidly eliminating pathogens and dead or dying cells, while also influencing the magnitude and duration of the inflammatory immune response. Moreover, the complement system plays both neuroprotective and neurodestructive roles. In AD, dysregulation of the complement system contributes to excessive microglial phagocytosis of synapses, with such synaptic loss representing the major correlate to cognitive decline in the course of the disease. However, the detailed mechanism for complement activation in AD had remained poorly understood until the discovery that complement factors were aberrantly S-nitrosylated, representing a redox-mediated posttranslational modification that controls the complement cascade. Nitrosative stress, caused by excessive generation of reactive nitrogen species (RNS), including nitric oxide (NO)-related species, had been recognized as a critical factor in the pathogenesis and progression of AD. Recent publications highlighted in this review support the notion that the NO-related species support aberrant S-nitrosylation of complement proteins, leading to pathological activation of the complement system, thus contributing to synaptic loss in AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.